Successful management of recurrent Acanthamoeba keratitis using topical and systemic miltefosine
| Autor: | Talin Barisani-Asenbauer, J Walochnik, S Binder, Lamiss Mejdoubi |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Miltefosine
medicine.medical_specialty biology business.industry Leishmaniasis General Medicine Neomycin Favorable prognosis biology.organism_classification medicine.disease Propamidine Dermatology Acanthamoeba Ophthalmology chemistry.chemical_compound chemistry Acanthamoeba keratitis Immunology Miconazole Nitrate Medicine business medicine.drug |
| Zdroj: | Acta Ophthalmologica. 90 |
| ISSN: | 1755-375X |
| DOI: | 10.1111/j.1755-3768.2012.f095.x |
| Popis: | Purpose Acanthamoebae are ubiquitous free-living amoebae. As facultative pathogens, they are the causative agents of Acanthamoeba keratitis (AK), a sight-threatening ocular surface infection. AK can have a favorable prognosis when diagnosed and treated early in the disease course but available treatment options can remain ineffective even when started early. Methods Case presentation Results AK can have a favorable prognosis when diagnosed and treated early in the disease course but available treatment options can remain ineffective even when started early. We present a case of AK that was successfully treated with topical and systemic miltefosine after showing sight-threatening recurrences under recommended therapy including a combination of propamidine 0.1%, miconazole nitrate 1%, neomycin, diamide and cationic antiseptics over a 12 months period. Conclusion In previous studies, miltefosine (hexadecylphosphocholine), an alkylphosphocholine, approved for the oral and topical treatment of leishmaniasis, proved to be highly active against Acanthamoeba in vitro [Walochnik et al. 2002]. This has been confirmed by several other studies [e.g. Schuster et al. 2006, McBride et al. 2007, Walochnik et al. 2009, Polat et al.2012]. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text